# Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

> **NCT00771615** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 469 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK A/turkey H5N1 Influenza vaccine

## Key facts

- **NCT ID:** NCT00771615
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-16
- **Primary completion:** 2009-05-26
- **Final completion:** 2009-12-04
- **Target enrollment:** 469 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00771615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00771615, "Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00771615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*